India
· Delayed Price · Currency is INR Panacea Biotec Statistics
Total Valuation
Panacea Biotec has a market cap or net worth of INR 26.73 billion. The enterprise value is 25.13 billion.
| Market Cap | 26.73B |
| Enterprise Value | 25.13B |
Important Dates
The next estimated earnings date is Monday, May 26, 2025.
| Earnings Date | May 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Panacea Biotec has 61.25 million shares outstanding. The number of shares has decreased by -45.29% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 61.25M |
| Shares Change (YoY) | -45.29% |
| Shares Change (QoQ) | -2.02% |
| Owned by Insiders (%) | 68.71% |
| Owned by Institutions (%) | 0.03% |
| Float | 14.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.52 |
| PB Ratio | 3.27 |
| P/TBV Ratio | 3.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -317.55 |
| EV / Sales | 4.46 |
| EV / EBITDA | 252.98 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 2.17 |
| Debt / FCF | n/a |
| Interest Coverage | -9.07 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -1.82% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 2.91M |
| Profits Per Employee | -40,873 |
| Employee Count | 1,936 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +205.70% in the last 52 weeks. The beta is 0.92, so Panacea Biotec's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | +205.70% |
| 50-Day Moving Average | 381.11 |
| 200-Day Moving Average | 321.30 |
| Relative Strength Index (RSI) | 56.55 |
| Average Volume (20 Days) | 426,005 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Panacea Biotec had revenue of INR 5.63 billion and -79.13 million in losses. Loss per share was -1.36.
| Revenue | 5.63B |
| Gross Profit | 3.66B |
| Operating Income | -249.69M |
| Pretax Income | -100.33M |
| Net Income | -79.13M |
| EBITDA | 99.33M |
| EBIT | -249.69M |
| Loss Per Share | -1.36 |
Balance Sheet
The company has 1.77 billion in cash and 215.70 million in debt, giving a net cash position of 1.56 billion or 25.45 per share.
| Cash & Cash Equivalents | 1.77B |
| Total Debt | 215.70M |
| Net Cash | 1.56B |
| Net Cash Per Share | 25.45 |
| Equity (Book Value) | 8.29B |
| Book Value Per Share | 133.61 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 64.97%, with operating and profit margins of -4.43% and -1.41%.
| Gross Margin | 64.97% |
| Operating Margin | -4.43% |
| Pretax Margin | -1.78% |
| Profit Margin | -1.41% |
| EBITDA Margin | 1.76% |
| EBIT Margin | -4.43% |
| FCF Margin | n/a |
Dividends & Yields
Panacea Biotec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 45.29% |
| Shareholder Yield | 45.29% |
| Earnings Yield | -0.30% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |